Stay updated with breaking news from Pharma Intermediates. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The brokerage has a ‘buy’ recommendation on the stock with a target price of ₹528, indicating an upside of 10 percent from its current market price of ₹480.30.
Paragon Fine IPO: The initial public offering allotment will take place on November 1 and the shares are likely to be listed on the NSE SME on November 7
Aarti Drugs share price: On technical setup, the stock was last seen trading higher than the 5-day, 20-, 50-, 100- and 200-day moving averages. The counter's 14-day relative strength index (RSI) came at 83.71. A level below 30 is defined as oversold while a value above 70 is considered overbought. The company's stock has a price-to-earnings (P/E) ratio of 28.48 against a price-to-book (P/B) value of 4.24.
Eiko Lifesciences is currently trading at upper circuit limit of Rs. 74.60, up by 3.55 points or 5.00% from its previous closing of Rs. 71.05 on the BSE. The scrip opened at Rs. 73.98 and has touched a high and low of Rs. 74.60 and Rs. 73.00 respectively. So far 58227 shares were traded on
Gandhinagar, May 17 engaged in the manufacturing of Pharma Intermediates and APIs, Iodine derivatives has reported net profit of Rs. 9.49 crore for FY23, with Y-o-Y growth of 55.4% as compared to the net profit of Rs. 6.10 crore in FY22. Revenue from Operations grew 15.24% to Rs. 114.22 crore in FY23 as against revenue of Rs. 99.12 crore reported in FY22. Profit Before Tax during FY23 grew 50% to Rs. 12.95 crore as against Profit before Tax of Rs. 8.63 crore in FY22. EPS for FY23 is Rs. 18.67 per share.